copper(II) complex raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-14. Anything still debated is marked as such rather than presented as settled.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Peptide chain coordinated to a single metal ion |
| CAS number | 89030-95-5 | Indexed for the peptide-copper complex |
| Molecular formula | C14H22CuN6O4 | Approximate formula for a one-to-one complex |
| Appearance | Blue to violet solid | Color from copper d-d transitions |
| Solubility class | Freely soluble in water | Also dispersible in some polar solvents |
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
The problem, attributed to technical problems, is resolved by the following evening. 27 May – Post Office Limited issues an apology over the use of racist terms to describe postmasters wrongly investigated as part of the Horizon IT scandal. 28 May The Home Office announces it is launching an ad campaign on social media in Albania to deter migrants from coming to the UK; the campaign begins the following day. BBC News reports that Andrei Kelin, Russia's ambassador to the UK, has warned that the west's supply of weapons to Ukraine risks escalating the war to levels not seen so far. 29 May Mars bars, one of the top-selling chocolate bars in the UK, are given a new look with recyclable paper wrappers, in a bid to cut down on the growing problem of plastic waste. The Met Police's plan to stop attending emergency mental health incidents is described as "potentially alarming" by a former inspector of constabulary, with charity Mind also expressing concerns. 30 May Figures published by the British Retail Consortium show that supermarket prices rose in May, largely because of the price of coffee, chocolate and non-food goods. The UK government announces plans to close a loophole in the law that allows shopkeepers to give free vape samples to those under the age of majority. 31 May Two people die and eight others are injured during an incident at the beach in Bournemouth. ASLEF members hold their latest strike as part of an ongoing dispute over pay and conditions, causing widespread disruption to rail services.
== Tributes == "Referring to the death of Professor Brailsford Robertson yesterday, the Prime Minister (Mr. Scullin) said:— His untimely end has robbed Australia of a brilliant scientist, whose contribution to the Commonwealth's progress would always be remembered. On behalf of the Federal Ministry Mr. Scullin extended his sincere sympathy to Professor Robertson's family, and expressed its appreciation of the great national services which he had rendered." The Argus, 20 January 1930. "Professor Brailsford Robertson was one of Australia's most brilliant scientists. The value of the work he was accomplishing cannot be estimated." Hon. R.L. Butler, Premier of South Australia, 20 January 1930. "The main purpose of [Robertson's] studies was to solve the mystery of physical life in it successive stages of commencement, growth, decline, and cessation, for the benefit of his fellow-men. ... The amount of original work he accomplished in his short life was prodigious. I would be rash to assert that the loss to science, or as I should prefer to say, the loss to humanity, caused by his death is irreparable, but it will probably be a long time before anyone else is able to gather the threads together and produce the fabric he was attempting to weave on his loom." Sir George Murray, Chancellor of the University of Adelaide, 18 March 1932.
==== Stunted growth ==== Untreated OSA in children can also lead to stunted growth. When sleep is disrupted in children who are still growing, there can be significant consequences. Human growth hormone (HGH) is secreted during the night, especially during deep, non-REM sleep. If this is disrupted, growth hormone secretion may be compromised; thus, growth may not occur normally, and children may become shorter than their peers.
== Biological role == Dipicolinic acid composes 5% to 15% of the dry weight of Bacillus subtilis spores. It has been implicated as responsible for the heat resistance of the endospore, although mutants resistant to heat but lacking dipicolinic acid have been isolated, suggesting other mechanisms contributing to heat resistance are at work. Two genera of bacterial pathogens are known to produce endospores: the aerobic Bacillus and anaerobic Clostridium. Dipicolinic acid forms a complex with calcium ions within the endospore core. This complex binds free water molecules, causing dehydration of the spore. As a result, the heat resistance of macromolecules within the core increases. The calcium-dipicolinic acid complex also functions to protect DNA from heat denaturation by inserting itself between the nucleobases, thereby increasing the stability of DNA.
there were many isolated subdisciplines within neuroscience with little contact between them many people who were interested in behaviour treated the brain as a black box consciousness was viewed as a taboo subject by many neurobiologists Crick hoped he might aid progress in neuroscience by promoting constructive interactions between specialists from the many different subdisciplines concerned with consciousness. He also collaborated with neurophilosophers such as Patricia Churchland. In 1983, as a result of their studies of computer models of neural networks, Crick and Mitchison proposed that the function of REM sleep and dreaming is to remove certain modes of interactions in networks of cells in the mammalian cerebral cortex; they called this hypothetical process "reverse learning" or "unlearning". In the final phase of his career, Crick established a collaboration with Christof Koch that led to publication of a series of articles on consciousness during the period spanning from 1990 to 2005. Crick made the strategic decision to focus his theoretical investigation of consciousness on how the brain generates visual awareness within a few hundred milliseconds of viewing a scene. Crick and Koch proposed that consciousness seems so mysterious because it involves very short-term memory processes that are as yet poorly understood. In his book The Astonishing Hypothesis, Crick described how neurobiology had reached a mature enough stage so that consciousness could be the subject of a unified effort to study it at the molecular, cellular and behavioural levels.
Sources: en.wikipedia.org
=== Pharmacodynamics === ETH-LAD acts as a serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It shows greater potency and efficacy as a serotonin 5-HT2A receptor agonist than LSD in vitro. In addition to the serotonin 5-HT2A receptor, the drug binds with high affinity to the serotonin 5-HT1A and 5-HT2C receptors. Like LSD, ETH-LAD also binds with lower affinity to the dopamine D1, D2, D3, D4, and D5 receptors. ETH-LAD shows psychedelic-like effects in animals, specifically rodent drug discrimination tests. It is about 1.6- to 2.3-fold more potent than LSD in these tests. Similarly to LSD, ETH-LAD shows moderate anti-inflammatory effects in preclinical research, but with slightly higher potency.
Environmental health laboratories are governmental laboratories that conduct testing to protect human health and the environment. In some states, a single laboratory acts as both the environmental and the public health laboratory. In other states, the environmental laboratory is part of the department of environmental quality or natural resources while the public health laboratory is part of the health department. Environmental health laboratories help to identify contaminants by conducting regular testing of water, air, soil, food and other media to ensure that populations are not being exposed to unhealthy levels of contamination. APHL supports these laboratories by coordinating a response to environmental health issues. They assist in providing information and training to the scientists working in the labs, and serve as a link between member laboratories and federal agencies, including Centers for Disease Control and Prevention's (CDC) National Center for Environmental Health and the US Environmental Protection Agency.
The discovery of actinium by Debierne was however questioned in 1971 and 2000, arguing that Debierne's publications in 1904 contradicted his earlier work of 1899–1900. This view instead credits the 1902 work of Friedrich Oskar Giesel, who discovered a radioactive element named emanium that behaved similarly to lanthanum. The name actinium comes from the Ancient Greek: ακτίς, ακτίνος (aktis, aktinos), meaning beam or ray. This metal was discovered not by its own radiation but by the radiation of the daughter products. Owing to the close similarity of actinium and lanthanum and low abundance, pure actinium could only be produced in 1950. The term actinide was probably introduced by Victor Goldschmidt in 1937. Protactinium was possibly isolated in 1900 by William Crookes. It was first identified in 1913, when Kasimir Fajans and Oswald Helmuth Göhring encountered the short-lived isotope 234mPa (half-life 1.17 minutes) during their studies of the 238U decay chain. They named the new element brevium (from Latin brevis meaning brief); the name was changed to protoactinium (from Greek πρῶτος + ἀκτίς meaning "first beam element") in 1918 when two groups of scientists, led by the Austrian Lise Meitner and Otto Hahn of Germany and Frederick Soddy and John Arnold Cranston of Great Britain, independently discovered the much longer-lived 231Pa. The name was shortened to protactinium in 1949. This element was little characterized until 1960, when Alfred Maddock and his co-workers in the U.K.
== Signaling == Activation of the adenosine A1 receptor by an agonist causes binding of Gi1/2/3 or Go protein. Binding of Gi1/2/3 causes an inhibition of adenylate cyclase and, therefore, a decrease in the cAMP concentration. An increase of the inositol triphosphate/diacylglycerol concentration is caused by an activation of phospholipase C, whereas the elevated levels of arachidonic acid are mediated by DAG lipase, which cleaves DAG to form arachidonic acid. Several types of potassium channels are activated but N-, P-, and Q-type calcium channels are inhibited.
Sources: en.wikipedia.org
It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.
The tripeptide was first isolated from human plasma and has also been reported in saliva and urine. Plasma levels appear to decline with age in some small studies. Those observations rest on limited sample sizes.
It is not authorized as a systemic medicine in most countries. Cosmetic preparations list it as an ingredient rather than an active pharmaceutical substance. Legal status therefore differs by jurisdiction.
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).